Accuray Incorporated (ARAY): Price and Financial Metrics
ARAY Price/Volume Stats
Current price | $2.57 | 52-week high | $4.30 |
Prev. close | $2.61 | 52-week low | $2.36 |
Day low | $2.57 | Volume | 251,400 |
Day high | $2.63 | Avg. volume | 423,423 |
50-day MA | $2.70 | Dividend yield | N/A |
200-day MA | $3.01 | Market Cap | 254.86M |
ARAY Stock Price Chart Interactive Chart >
ARAY POWR Grades
- ARAY scores best on the Value dimension, with a Value rank ahead of 95.26% of US stocks.
- ARAY's strongest trending metric is Quality; it's been moving down over the last 26 weeks.
- ARAY's current lowest rank is in the Momentum metric (where it is better than 4.37% of US stocks).
ARAY Stock Summary
- ACCURAY INC's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than 95.73% of US listed stocks.
- Price to trailing twelve month operating cash flow for ARAY is currently 37.97, higher than 89.99% of US stocks with positive operating cash flow.
- ARAY's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of 87.84% of US stocks.
- Stocks that are quantitatively similar to ARAY, based on their financial statements, market capitalization, and price volatility, are SRI, PAR, LPSN, KLTR, and KOPN.
- Visit ARAY's SEC page to see the company's official filings. To visit the company's web site, go to www.accuray.com.
ARAY Valuation Summary
- ARAY's price/earnings ratio is -40.4; this is 238.59% lower than that of the median Healthcare stock.
- Over the past 206 months, ARAY's price/sales ratio has gone down 13.9.
Below are key valuation metrics over time for ARAY.
Stock | Date | P/S | P/B | P/E | EV/EBIT |
---|---|---|---|---|---|
ARAY | 2023-12-29 | 0.6 | 5.4 | -40.4 | -147.6 |
ARAY | 2023-12-28 | 0.6 | 5.5 | -41.5 | -150.4 |
ARAY | 2023-12-27 | 0.6 | 5.7 | -43.0 | -154.0 |
ARAY | 2023-12-26 | 0.6 | 5.7 | -42.4 | -152.6 |
ARAY | 2023-12-22 | 0.6 | 5.5 | -41.0 | -149.0 |
ARAY | 2023-12-21 | 0.6 | 5.5 | -41.0 | -149.0 |
ARAY Growth Metrics
- Its 3 year revenue growth rate is now at 3.77%.
- Its 2 year cash and equivalents growth rate is now at 7.21%.
- The year over year net cashflow from operations growth rate now stands at -83.5%.
The table below shows ARAY's growth in key financial areas (numbers in millions of US dollars).
Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
---|---|---|---|
2022-12-31 | 417.445 | -44.379 | -11.821 |
2022-09-30 | 418.96 | 6.246 | -9.768 |
2022-06-30 | 429.909 | -2.4 | -5.347 |
2022-03-31 | 430.822 | 8.439 | -12.987 |
2021-12-31 | 437.215 | 46.109 | -12.331 |
2021-09-30 | 418.399 | 32.782 | -7.741 |
ARAY's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- ARAY has a Quality Grade of C, ranking ahead of 70.31% of graded US stocks.
- ARAY's asset turnover comes in at 0.83 -- ranking 35th of 186 Medical Equipment stocks.
- ATRC, INGN, and GKOS are the stocks whose asset turnover ratios are most correlated with ARAY.
The table below shows ARAY's key quality metrics over time.
Period | Asset Turnover | Gross Margin | ROIC |
---|---|---|---|
2021-06-30 | 0.830 | 0.403 | -0.014 |
2021-03-31 | 0.792 | 0.409 | 0.018 |
2020-12-31 | 0.785 | 0.411 | 0.025 |
2020-09-30 | 0.787 | 0.402 | 0.042 |
2020-06-30 | 0.796 | 0.391 | 0.016 |
2020-03-31 | 0.866 | 0.385 | 0.015 |
ARAY Price Target
For more insight on analysts targets of ARAY, see our ARAY price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
Average Price Target | $8.20 | Average Broker Recommendation | 1.3 (Strong Buy) |
Accuray Incorporated (ARAY) Company Bio
Accuray Inc. designs, develops, and sells radio-surgery and radiation therapy systems for the treatment of tumors in the body. It offers the CyberKnife System, a robotic stereotactic radio-surgery and stereotactic body radiation therapy system used for the treatment of various types of cancer and tumors in the body. The company was founded in 1990 and is based in Sunnyvale, California.
Latest ARAY News From Around the Web
Below are the latest news stories about ACCURAY INC that investors may wish to consider to help them evaluate ARAY as an investment opportunity.
Accuray (ARAY) Launches VitalHold in Japan for Use With RadixactAccuray's (ARAY) VitalHold is likely to transform breast cancer treatment in Japan by integrating SGRT for precise radiotherapy. It may become a game-changer for patients and medical staff. |
Accuray Initiates Sales of the VitalHold™ Solution in Japan, Supporting Surface-guided Radiation Therapy on the Radixact® SystemAccuray Incorporated (NASDAQ: ARAY) announced today that the company has initiated sales of the VitalHold™* package supporting surface-guided radiation therapy (SGRT) on the Radixact® System in Japan beginning November 30, 2023. The VitalHold feature incorporates SGRT capability on the Radixact System using the Catalyst+ HD system manufactured by C-RAD, making it possible to deliver deep inspiration breath hold (DIBH) treatments, primarily for breast cancers, and perform markerless patient setup |
Insider Sell Alert: President Suzanne Winter Sells 65,390 Shares of Accuray Inc (ARAY)Accuray Incorporated (NASDAQ:ARAY), a company specializing in the development, manufacturing, and selling of radiotherapy systems for alternative cancer treatments, has recently witnessed a significant insider sell from one of its top executives. |
Accuray Incorporated (NASDAQ:ARAY) Q1 2024 Earnings Call TranscriptAccuray Incorporated (NASDAQ:ARAY) Q1 2024 Earnings Call Transcript November 7, 2023 Accuray Incorporated reports earnings inline with expectations. Reported EPS is $-0.03 EPS, expectations were $-0.03. Operator: Good afternoon and welcome to the Accuray’s First Quarter 2024 Conference Call. [Operator Instructions] Please note that this event is being recorded. I would now like to turn […] |
Accuray (ARAY) Q1 Earnings In-Line With Estimates, Revenues TopAccuray (ARAY) reports a solid fiscal first quarter top line on the back of robust Product revenues. |
ARAY Price Returns
1-mo | -7.55% |
3-mo | -7.55% |
6-mo | -4.81% |
1-year | -7.55% |
3-year | -50.48% |
5-year | -46.46% |
YTD | -9.19% |
2023 | 35.41% |
2022 | -56.18% |
2021 | 14.39% |
2020 | 47.87% |
2019 | -17.30% |
Continue Researching ARAY
Want to see what other sources are saying about Accuray Inc's financials and stock price? Try the links below:Accuray Inc (ARAY) Stock Price | Nasdaq
Accuray Inc (ARAY) Stock Quote, History and News - Yahoo Finance
Accuray Inc (ARAY) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...